This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Factor IX deficiency with functional defect제9인자결핍(기능적 결함을 동반) (기능이상형 제구인자결핍증)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: D67 (hereditary factor IX deficiency) | Special Copayment Reduction: V009 (rare disease, 10% copayment for 5 years after registration)
B. SynonymsCRM-positive hemophilia B, dysfunctional-type hemophilia B, Factor IX:C deficiency with normal antigen, Dysfunctional factor IX deficiency, Hemophilia B CRM+, hemophilia B functional-defect variant
C. Adult onsetLikelihood of first presentation in adulthood: considerable — functional-defect hemophilia B (CRM-positive) mostly has a mild to moderate phenotype with rare spontaneous bleeding, and many adult cases are first diagnosed after age 18 following surgery, tooth extraction or trauma; FIX:Ag is normal but FIX:C is reduced, so it is sometimes discovered incidentally from a prolonged APTT on a routine checkup.
1. HistoryIntroduction of the CRM concept, establishment of CRM+ hemophilia B, F9 cloning, FIX Leyden, the NGS era
2. CausesF9 missense mutations, Gla·EGF·SP domain abnormalities, normal protein synthesis·functional defect
3. GeneticsF9 Xq27.1, 34 kb, 8 exons, 415 aa, 55 kDa, X-linked recessive, variant characteristics by domain
4. Epidemiology5–10% of all hemophilia B, about 8,000–16,000 people worldwide, frequent diagnostic delay
5. PathophysiologyReduced tenase complex efficiency, insufficient FXa generation, reduced thrombin generation
6. SymptomsProlonged APTT, reduced FIX:C, normal FIX:Ag, mild to moderate bleeding, assay discrepancy
7. SignsFIX:Ag/FIX:C ratio >2, low inhibitor incidence, chromogenic/one-stage assay discrepancy
8. ScreeningAPTT → FIX:C (one-stage + chromogenic) → FIX:Ag → Ag/C ratio → F9 NGS
9. DiagnosisAg/C ratio calculation, identification of missense variant, differentiation by vitamin K response in Gla domain variants
10. TreatmentFIX concentrates (including EHL), emicizumab, fitusiran, DDAVP ineffective
11. PrognosisMostly mild to moderate phenotype, normal life expectancy with appropriate treatment, low inhibitor rate
12. PreventionGenetic counseling, carrier F9 analysis, PGT, preoperative FIX replacement planning
13. References10 major international guidelines and original articles

1. History

After hemophilia B (Christmas disease) was reported by Biggs et al. in 1952 as a distinct disease separate from hemophilia A, researchers gradually recognized that considerable heterogeneity exists between clinical phenotype and laboratory results even among patients with hemophilia B. The concept that became central in uncovering the cause of this heterogeneity was CRM (cross-reacting material).

The CRM concept was originally introduced first in factor VIII (FVIII) research in the early 1960s. At the time, researchers found that in the plasma of some patients with hemophilia A, FVIII coagulant activity (FVIII:C) was undetectable, yet a substance reacting with anti-FVIII antiserum was present. Such proteins that react immunologically with antiserum but lack or have greatly reduced functional activity were called CRM-positive (CRM+) or cross-reacting material-positive, and cases lacking both activity and antigen were defined as CRM-negative (CRM−).

This concept was soon applied to factor IX (FIX) research as well. As immunoassays using anti-FIX antiserum were established during the 1960s–70s, reports began to appear that in some patients with hemophilia B, FIX coagulant activity (FIX:C) was markedly low while FIX antigen (FIX:Ag) measured at normal or near-normal levels. These CRM+ hemophilia B patients had intact protein synthesis but were producing functionally defective FIX molecules, suggesting a subtype of hemophilia B caused by dysfunction rather than protein deficiency.

The cDNA cloning of human FIX by Kurachi and Davie in 1982, and the complete elucidation of the genomic structure of the F9 gene in 1985, provided a decisive foundation for exploring the molecular basis of CRM+ hemophilia B. The F9 gene is located on the long arm of the X chromosome (Xq27.1) and is a 34-kilobase (kb) gene consisting of 8 exons that encodes a 55 kDa vitamin K-dependent protease of 415 amino acids. Molecular analyses performed after F9 gene cloning confirmed that the F9 gene of CRM+ hemophilia B patients characteristically harbors missense mutations rather than large deletions or frameshift mutations. These point mutations are located in specific functional domains of the FIX protein, particularly the Gla domain, EGF domains, activation peptide or serine protease (SP) domain, and selectively impair only function without affecting FIX synthesis or secretion.

A particularly notable finding is the FIX Leyden phenotype. This variant, first reported in the Leiden region of the Netherlands, carries mutations in the promoter region of the F9 gene. Patients with FIX Leyden show the clinical picture of severe hemophilia B in childhood but display a unique course in which FIX:C rises spontaneously through puberty and recovers to a mild level. In 1992, Crossley et al. elucidated the mechanism by which androgens (male hormones) secreted at puberty bind to the androgen response element of the F9 promoter and increase FIX gene expression. This finding showed that mutations in gene regulatory regions can also cause functional FIX deficiency, while revealing the remarkable biological phenomenon of hormone-mediated recovery of gene expression.

From the 1990s onward, as large gene mutation databases were built, lists of CRM+ variants began to be compiled systematically. The most comprehensive databases at present, the Human Gene Mutation Database (HGMD) and F9 gene-specific databases, contain hundreds of missense mutations, many of which have been confirmed to be associated with the CRM+ phenotype. The spread of next-generation sequencing (NGS) technology in the 2010s further accelerated research on CRM+ variants, allowing rare missense variants that were previously difficult to identify to be registered on a large scale.

Recently, discrepancies in FIX:C measurements between the one-stage assay (OSA) and the chromogenic substrate assay (CSA) have also begun to be reported in CRM+ variants. FIX proteins with some missense variants show different activity values in the two assays, which has important clinical implications when setting treatment targets or determining prophylactic doses. These discrepancies are understood to reflect that the variant FIX behaves differently under particular conditions (e.g., presence or absence of phospholipids, thrombin activation conditions).

2. Causes

Factor IX deficiency with functional defect is caused mainly by missense mutations in the F9 gene (Xq27.1). A missense mutation is the substitution of one amino acid for another through a single nucleotide change, resulting in an FIX protein that is synthesized and secreted at normal or near-normal levels but is functionally defective.

In this respect, CRM+ variants differ fundamentally from inversions, large deletions, frameshift mutations or nonsense mutations. The latter variants block or severely reduce FIX protein synthesis itself, so FIX:Ag is also reduced (CRM− phenotype), whereas in missense mutations protein production is maintained and only its function is impaired.

Missense mutations causing the CRM+ phenotype are distributed across several functional domains of the FIX protein. The Gla domain (γ-carboxyglutamic acid domain) is the region where glutamic acid residues are converted to γ-carboxyglutamic acid (Gla) by a vitamin K-dependent enzyme, and this conversion is essential for calcium ion-mediated phospholipid membrane binding. Missense variants in the Gla domain interfere with this carboxylation, preventing FIX from binding properly to the activation site (phospholipid membrane surface) and thereby lowering FIX:C. A representative example is the Glu27Lys variant.

Variants in the EGF-1 domain impair binding to FVIIIa (the cofactor of the intrinsic tenase complex) or to the tissue factor-FVIIa complex. Variants in the EGF-2 domain can affect the structural stability of FIXa after activation. Variants in the activation peptide region reduce the efficiency of FIX cleavage and activation by FXIa or FVIIa. Variants in the serine protease (SP) domain impair FX substrate recognition or catalytic activity itself, slowing the rate at which the tenase complex activates FX.

Promoter-region mutations (FIX Leyden type) are not missense mutations in the strict sense, but because they result in reduced functional FIX expression, they are sometimes included in the functional-defect type in a broad sense. In this case, they show the unusual course of partial recovery of FIX expression in adulthood due to androgens.

3. Genetics

The F9 gene is located at band 27.1 of the long arm of the X chromosome (Xq27.1), with a total size of about 34 kilobases (kb), and consists of 8 exons. The mature FIX protein is a vitamin K-dependent serine protease precursor (zymogen) of 415 amino acids with a molecular weight of about 55 kDa, synthesized in hepatocytes. F9 follows an X-linked recessive inheritance pattern, so the disease occurs in hemizygous males, while heterozygous females are in principle carriers but may show some symptoms depending on lyonization (skewed X chromosome inactivation).

The domain structure of the FIX protein is arranged from the N-terminus in the order signal peptide → propeptide → Gla domain → hydrophobic stack → EGF-1 domain → EGF-2 domain → activation peptide → serine protease (SP) domain. Each domain has a specific function, and missense variants in each domain show predictable patterns of functional impairment.

The main variant types causing the CRM+ phenotype can be summarized by domain as follows. Gla domain variants (e.g., Glu27Lys, Glu26Lys): impaired vitamin K-dependent carboxylation → reduced FIX:C, normal FIX:Ag. In this group, FIX:C sometimes rises slightly with vitamin K administration, which provides a clue for differentiation from vitamin K-dependent coagulation disorders. EGF-1 domain variants: reduced binding affinity for FVIIIa or tissue factor-FVIIa → reduced efficiency of tenase complex formation. Activation peptide variants: reduced efficiency of activating cleavage of FIX by FXIa or FVIIa → reduced FIXa generation per unit time. SP domain variants: impaired FX substrate recognition or amidolytic activity → reduced FX-activating capacity per FIXa molecule.

The ratio of FIX:Ag to FIX:C, that is, an FIX:Ag/FIX:C ratio of 2 or higher, strongly suggests the CRM+ phenotype. In normal individuals this ratio is approximately 1:1. FIX Leyden variants are located in the promoter region (at several positions such as −6, −20 and −26) and hinder access of transcription factors that bind the androgen response element, but after puberty androgens activate FIX transcription through an alternative pathway. FIX Padua (p.Arg338Leu) is a gain-of-function variant with FIX:C more than 8 times higher than in normal individuals and is associated with increased thrombotic risk; in gene therapy, this variant is used in a strategy to achieve sufficient hemostatic effect with only a small amount of FIX expression.

4. Epidemiology

Functional-defect (CRM+) hemophilia B is estimated to account for about 5–10% of all patients with hemophilia B. Because the prevalence of hemophilia B itself is about 1 in 25,000–30,000 male births, the absolute prevalence of the CRM+ functional-defect type is very rare, at about 1 in 250,000–600,000 male births. Worldwide, about 8,000–16,000 people are estimated to have this subtype, but the estimates vary widely depending on differences in diagnostic criteria and how widely FIX:Ag measurement is used.

No marked differences in prevalence by race or region have been reported, but certain missense variants (e.g., the FIX Leyden type) have been reported relatively more often in populations of European descent. This is interpreted as being due to a founder effect.

Because CRM+ hemophilia B mostly shows a mild to moderate phenotype, diagnosis is often delayed. It is not uncommon for abnormal hemostasis to be first discovered in bleeding-provoking situations such as surgery, tooth extraction or childbirth without spontaneous joint bleeding or muscle hematoma, or for a prolonged APTT to be found incidentally on a blood test and diagnosed through further testing. As a result, the actual affected population may be higher than official registry figures. Separate statistics on the CRM+ subtype in the databases of the Korea Rare Disease Foundation and the Korea Hemophilia Foundation (KBDR) are still limited, but about 40–75 people, or 5–10% of all registered hemophilia B patients (about 750), are estimated to fall into this category.

The proportion of de novo mutations is known to be about 30% of all hemophilia B, and a similar proportion is estimated to apply to CRM+ variants. This means that sporadic cases without a maternal carrier account for about one-third of the total, suggesting that the diagnosis should be kept open even when there is no family history.

5. Pathophysiology

In the normal intrinsic coagulation pathway, factor IX (FIX) is activated to FIXa by FXIa or by the tissue factor-FVIIa complex of the extrinsic pathway. FIXa forms the intrinsic tenase complex together with FVIIIa (cofactor), calcium ions (Ca²⁺) and a negatively charged phospholipid membrane surface, and this complex activates factor X (FX) to FXa. FXa forms the prothrombinase complex with FVa and converts prothrombin (FII) to thrombin (FIIa), and thrombin polymerizes fibrinogen into fibrin to form a stable clot.

In CRM+ functional-defect hemophilia B, the FIX protein is synthesized and secreted, but its function is impaired by one or more of the following mechanisms. First, reduced efficiency of activation by FXIa: variants in the activation peptide region reduce the rate (kcat/Km) at which FXIa cleaves FIX and converts it to FIXa. Second, impaired binding to FVIIIa or tissue factor-FVIIa: EGF-1 domain variants reduce the efficiency with which FIXa forms a complex with its cofactor. Third, impaired phospholipid membrane binding: Gla domain variants reduce phospholipid membrane binding of FIX (or FIXa), so the tenase complex cannot form at the activation site. Fourth, reduced FX substrate recognition or catalytic activity: SP domain variants reduce the substrate specificity or amidolytic efficiency of FIXa.

All of these mechanisms ultimately result in reduced FXa generation by the tenase complex, leading to insufficient thrombin generation, reduced fibrin formation and hemostatic failure. The degree of bleeding tendency is proportional to the residual level of FIX function (FIX:C); FIX:C below 1% is classified as severe, 1–5% as moderate and 5–40% as mild. Because function is reduced in patients with CRM+ variants even though protein levels are normal, it is clinically appropriate to assess the phenotype by FIX:C alone.

6. Symptoms

The clinical symptoms of functional-defect hemophilia B are determined by the residual level of FIX function, and most fall into the mild to moderate category. This is because CRM+ variants mainly cause partial impairment of protein function, so the phenotype is relatively milder than with CRM− variants, which cause complete loss of the protein.

In mild patients (FIX:C 5–40%), spontaneous bleeding during ordinary physical activity almost never occurs. The main symptoms are delayed or excessive bleeding after surgery or tooth extraction, hematomas after trauma (intramuscular or subcutaneous), and heavy menstrual bleeding or postpartum hemorrhage in female carriers. These patients are often undiagnosed until adulthood because they have no symptoms, and some are diagnosed after further testing when a prolonged activated partial thromboplastin time (APTT) is found on routine blood tests.

In moderate patients (FIX:C 1–5%), spontaneous bleeding may occasionally occur after severe trauma, and hemarthrosis or muscle hematomas are not uncommon. With recurrent joint bleeding, there is a possibility of progression to chronic hemophilic arthropathy.

A unique clinical course is observed in the FIX Leyden variant. In childhood, FIX:C is very low (often below 1%) and bleeding symptoms resemble severe hemophilia, but through puberty FIX:C rises spontaneously and recovers to a mild level (5–40%). In adulthood, patients show only relatively mild symptoms even without prophylaxis, and some patients can lead a normal daily life without treatment.

The characteristic laboratory finding is isolated APTT prolongation (prothrombin time, PT, is normal). FIX:C is reduced, but the degree varies with the variant type. FIX:Ag is normal or mildly reduced, and an FIX:Ag/FIX:C ratio of 2 or higher is the key laboratory finding of the CRM+ phenotype. In some missense variants, FIX:C values measured by the one-stage assay (OSA) and the chromogenic substrate assay (CSA) may be discordant.

7. Signs

The main laboratory sign of functional-defect hemophilia B is that only FIX:C is disproportionately reduced while FIX:Ag is normal or mildly reduced. Expressed quantitatively, this is an FIX:Ag/FIX:C ratio > 2, and this finding is used as a marker of the CRM+ phenotype.

Assay discrepancy between the one-stage assay and the chromogenic substrate assay is an important clinical sign. The one-stage assay calculates FIX:C based on the activated partial thromboplastin time (APTT) in recalcified plasma, whereas the chromogenic substrate assay uses purified reagents to directly measure the conversion of FX → FXa by FIXa activity. FIX molecules with certain missense variants behave differently under the two conditions, producing a significant difference between the two measurements. The chromogenic assay tends to predict the clinical bleeding phenotype more accurately, but which assay is more reliable may differ by variant type, so performing both methods in parallel is recommended.

Inhibitor incidence is low at 3–5% even in ordinary hemophilia B (CRM− type) compared with hemophilia A (25–30%), and it tends to be even lower in the CRM+ functional-defect type. This is explained by the fact that in CRM+ patients the FIX protein is normally present, so immune tolerance is maintained and antibody formation against FIX replacement therapy is suppressed. Inhibitors tend to develop mainly in patients with CRM− variants (large deletions, nonsense).

On physical examination, signs of hemophilic arthropathy such as joint swelling, warmth and limited range of motion may be observed in patients with recurrent bleeding. However, mild patients often have no physical examination findings. In Gla domain variants, a slight rise in FIX:C after vitamin K administration may be observed, which helps distinguish it from vitamin K-dependent coagulation factor deficiency or use of vitamin K antagonists (warfarin).

8. Screening

Screening for functional-defect hemophilia B begins in the same way as the usual diagnostic process for hemophilia B, but additional steps are needed to identify the CRM+ subtype. The standard screening algorithm is as follows.

Step 1: APTT measurement — A prolonged activated partial thromboplastin time (APTT) with a normal prothrombin time (PT) suggests deficiency in the intrinsic coagulation pathway (FVIII, FIX, FXI, FXII). The degree of APTT prolongation depends on the FIX:C level, and in mild cases there may be only slight prolongation or a borderline level.

Step 2: Measurement of individual factor activity — After confirming APTT prolongation, FVIII:C and FIX:C are measured in sequence. If FVIII:C is normal and FIX:C is reduced, hemophilia B can be diagnosed. For FIX:C measurement, it is recommended to perform both the one-stage assay and the chromogenic substrate assay, and a discrepancy between the two values is a clue suggesting a CRM+ variant.

Step 3: FIX:Ag measurement — In patients with reduced FIX:C, FIX antigen (FIX:Ag) is measured by ELISA or electroimmunodiffusion. If FIX:C is disproportionately low while FIX:Ag is within the normal range (50–150%) or mildly reduced, the CRM+ phenotype is strongly suggested.

Step 4: Calculation of the FIX:Ag/FIX:C ratio — A ratio of 2 or higher is classified as the CRM+ functional-defect type. At this step, if a Gla domain variant is suspected (e.g., accompanying reduction of vitamin K-dependent coagulation factors, no history of warfarin use), observing the change in FIX:C before and after vitamin K administration can provide additional information.

Step 5: F9 gene analysis — Missense mutations are identified by a next-generation sequencing (NGS) panel or Sanger sequencing of all exons of the F9 gene. The promoter region should also be included in the analysis to exclude the FIX Leyden type. Inhibitor testing (Bethesda assay) is also performed for treatment planning.

When there is a patient with hemophilia B in the family, screening is possible in the neonatal period by measuring FIX:C in cord blood or peripheral blood, but because FIX:C is physiologically low in the neonatal period (30–50% of adult reference values), retesting after 6 months is necessary. Because FIX:C can also be reduced to varying levels in heterozygous carrier females, FIX:C measurement is recommended for carrier diagnosis and bleeding risk assessment.

9. Diagnosis

Functional-defect hemophilia B is confirmed in two steps: calculation of the FIX:Ag/FIX:C ratio and identification of an F9 missense variant. Clinically, the diagnosis is considered when the following criteria are met: (1) reduced FIX:C (below 40%), (2) normal or mildly reduced FIX:Ag, (3) FIX:Ag/FIX:C ratio ≥ 2, (4) normal PT, and (5) normal other coagulation factors (FVIII, FXI, etc.).

For molecular diagnosis, Sanger sequencing or NGS analysis of all exons (8) of the F9 gene and adjacent intron-exon junctions is performed. The diagnosis is confirmed when a missense mutation consistent with the CRM+ phenotype is identified. The pathogenicity of the variant found is assessed according to the ACMG/AMP guidelines and compared with lists of CRM+ variants registered in the existing literature and databases (e.g., ClinVar, HGMD). For novel missense variants not previously reported, it is ideal to confirm pathogenicity with in vitro functional testing.

The differential diagnosis should consider the following. Vitamin K-dependent coagulation factor deficiency (VKCFD): FII, FVII, FIX and FX are all reduced due to GGCX or VKORC1 gene variants, whereas in CRM+ hemophilia B with a Gla domain variant only FIX is selectively affected. Warfarin use: vitamin K antagonists also inhibit Gla domain carboxylation and can lower FIX:C, but this is distinguished by recovery after stopping the drug and by history. CRM− hemophilia B: FIX:Ag is also reduced, so the FIX:Ag/FIX:C ratio remains around 1. Hemophilia A: distinguished by reduced FVIII:C and normal FIX:C.

When there is a discrepancy between one-stage FIX:C and chromogenic FIX:C, the chromogenic value tends to correlate better with the clinical bleeding phenotype, so it is recommended to refer primarily to the chromogenic result when setting treatment targets. However, which assay is more appropriate may vary with the variant type, so the decision is made by integrating the individual patient's bleeding history and test results.

10. Treatment

The treatment principles for functional-defect hemophilia B are the same as for standard hemophilia B. DDAVP (desmopressin) transiently increases FVIII in (mild) hemophilia A but has no significant effect on FIX, so it is not used in this disease.

FIX concentrates are the mainstay of bleeding treatment and prophylaxis. Standard half-life (SHL) products include the recombinant FIX products BeneFIX (nonacog alfa) and Rixubis (nonacog gamma), administered by intravenous injection. The half-life of standard half-life FIX is about 18–24 hours (longer than the 12 hours of FVIII), allowing prophylaxis with relatively less frequent injection intervals than in hemophilia A.

Extended half-life (EHL) FIX products are widely used in clinical practice. Alprolix (eptacog beta, FIX-Fc fusion, half-life about 82 hours) can be given once weekly or every other week. Idelvion (albutrepenonacog alfa, FIX-albumin fusion, half-life about 104 hours) can be given once weekly to once every 2 weeks. Rebinyn (nonacog beta pegol) extends the half-life with PEGylation technology and can be given once weekly. The introduction of EHL products has greatly reduced the frequency of intravenous injections, improving patient adherence and quality of life.

Emicizumab is a bispecific antibody that mimics the function of FVIIIa, binding FIX (FIXa) and FX simultaneously instead of FVIII to substitute for the function of the tenase complex. It was originally developed for patients with hemophilia A, but because it can restore tenase complex function without directly replacing FIX, it may be applied to patients with hemophilia B who have developed inhibitors or who have difficulty accessing FIX products. It is given by subcutaneous injection once weekly, every other week or once every 4 weeks.

Fitusiran is an RNAi therapeutic targeting antithrombin (AT) that can be applied to both hemophilia A and B through a mechanism of reducing AT to increase thrombin generation. It is given by subcutaneous injection once a month. Its therapeutic effect in hemophilia B has been confirmed in clinical trials (Mahlangu et al. 2023), and it has the advantage of being usable regardless of inhibitor status.

When chromogenic assay values are discordant with the one-stage assay, setting treatment targets based on chromogenic FIX:C is more reliable. Target FIX:C levels (peak and trough) around surgery or during bleeding episodes follow the WFH guidelines but are determined by integrating the individual patient's actual test values and clinical response.

11. Prognosis

The prognosis of patients with functional-defect hemophilia B is generally good. Because most have a mild to moderate phenotype, spontaneous severe bleeding is rare, and with appropriate treatment and prophylaxis life expectancy can reach a level equivalent to the general population.

In patients with the FIX Leyden variant, the unusual course in which the severe bleeding tendency of childhood naturally lessens after puberty has a positive effect on prognosis. In adulthood after puberty, the intensity of prophylaxis can sometimes be reduced or stopped, but this must be decided based on the individual patient's FIX:C level and bleeding history.

Inhibitor incidence tends to remain even lower in the CRM+ functional-defect type than in ordinary hemophilia B (3–5%). Because the FIX protein is normally present, immune tolerance to endogenous FIX is maintained and the likelihood of antibody formation against exogenous FIX products is low. The rarity of inhibitors means that the efficiency of FIX replacement therapy is maintained, which is a positive factor for long-term prognosis.

The risk of chronic hemophilic arthropathy is determined mainly by the FIX:C level. In mild patients (FIX:C 5–40%), spontaneous joint bleeding is rare, so the risk of joint damage is low. However, when there has been recurrent traumatic joint bleeding, joint damage can accumulate, so regular assessment of joint status and physical therapy are recommended.

Gene therapy is currently advancing for hemophilia B as a whole, and etranacogene dezaparvovec (Hemgenix), approved by the FDA in 2022, uses an AAV5 vector carrying the FIX Padua variant with the aim of sustained FIX expression. Data are accumulating on whether this treatment is applicable to patients with CRM+ variants, and in the long term, near-curative treatment outcomes are expected for all patients with hemophilia B, including those with the CRM+ functional-defect type.

12. Prevention

Prevention of functional-defect hemophilia B can be divided into four areas: genetic counseling, carrier testing, prenatal diagnosis and bleeding prophylaxis.

Genetic counseling should be provided to all families in which a patient with hemophilia B has been identified. It provides an explanation of the X-linked recessive inheritance pattern, the risk of an affected male birth (50% for carrier females), the possibility of bleeding in carrier females (some carriers may experience mild hemophilia symptoms due to skewed X chromosome inactivation), and information on reproductive options.

Carrier F9 gene analysis is performed in female family members such as the mother, sisters and daughters of patients with hemophilia B. When the family's causative variant is already known, specific testing for that variant is sufficient; when it is not known, NGS analysis of all exons and the promoter of the F9 gene is performed. FIX:C measurement in carrier females is also useful for assessing bleeding risk.

Prenatal diagnosis is performed by obtaining fetal DNA through chorionic villus sampling (CVS) at 11–14 weeks of gestation or amniocentesis at 15–18 weeks and performing F9 gene analysis. Recently, preimplantation genetic testing (PGT) combined with in vitro fertilization (IVF) has made selection possible already at the embryo stage. Non-invasive prenatal testing (NIPT) technology is also developing, but its clinical introduction in hemophilia diagnosis is still limited.

A DDAVP response test is sometimes tried in mild hemophilia A as an alternative to preoperative FIX infusion, but because DDAVP has no significant effect on FIX in hemophilia B and the CRM+ functional-defect type, it is important to confirm the lack of DDAVP response in advance and plan FIX product administration beforehand. Before surgery or invasive procedures, an FIX replacement plan (target FIX:C, dose, dosing interval, monitoring schedule) must be established in collaboration with a hemophilia specialist.

Primary prophylaxis is the initiation of regular FIX infusion before the first joint bleed or before age 2 and is recommended for severe and moderate patients to prevent hemophilic arthropathy. In the CRM+ functional-defect type as well, whether to apply prophylaxis is decided according to the FIX:C level. In mild patients, on-demand treatment is often sufficient, but prior FIX replacement is needed when there is a bleeding tendency or ahead of surgery or bleeding-provoking situations.

13. References

  1. Srivastava A, et al. WFH Guidelines for the Management of Haemophilia, 3rd ed. Haemophilia. 2020;26(S6):1-158.
  2. Biggs R, Douglas AS, Macfarlane RG, et al. Christmas disease: a condition previously mistaken for haemophilia. BMJ. 1952;2(4799):1378-1382.
  3. Crossley M, Ludwig M, Stowell KM, De Vos P, Olek K, Brownlee GG. Recovery from hemophilia B Leyden: an androgen-responsive element in the factor IX promoter. Science. 1992;257(5068):377-379.
  4. Pipe SW, Leebeek FWG, Recht M, et al. Gene therapy with etranacogene dezaparvovec for hemophilia B. N Engl J Med. 2023;388(8):706-718.
  5. Mahlangu J, Ragni MV, Gupta N, et al. Fitusiran prophylaxis in patients with haemophilia A or B. N Engl J Med. 2023;389(20):1843-1855.
  6. Oldenburg J, Ananyeva NM, Saenko EL. Molecular basis of haemophilia A. Haemophilia. 2004;10 Suppl 4:133-139.
  7. Lenting PJ, van Mourik JA, Mertens K. The life cycle of coagulation factor VIII in view of its structure and function. Blood. 1998;92(11):3983-3996.
  8. Nair S, Ghosh K, Shetty S. One stage versus chromogenic FVIII assay discrepancy in haemophilia A patients and its significance. Haemophilia. 2016;22(1):e41-e44.
  9. Mannucci PM, Tuddenham EG. The hemophilias — from royal genes to gene therapy. N Engl J Med. 2001;344(23):1773-1779.
  10. Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet. 2003;361(9371):1801-1809.